Zusammenfassung
M. Fabry ist eine X-chromosomal vererbte Lipidstoffwechselerkrankung, die durch das Fehlen oder die verminderte Aktivität des α-Galaktosidase-A-Enzyms gekennzeichnet ist. Der mangelnde Katabolismus führt zu einer systemischen Ablagerung von Glykosphyngolipiden und multiplen Organschäden mit tödlichem klinischen Verlauf in der vierten oder fünften Lebensdekade. Es wird der Fall eines männlichen 33-jährigen Patienten mit M. Fabry und die typischen neurologischen Symptome dieser Erkrankung in Form von Schlaganfällen im jungen Erwachsenenalter und qualvolle neuropathische Schmerzen berichtet. Darüber hinaus werden Klinik und Diagnostik dieser höchst seltenen Erkrankung beschrieben. Therapeutisch stellt die seit dem letzten Kalenderjahr mögliche rekombinante Enzymersatztherapie einen entscheidenden und viel versprechenden Wendepunkt in der Behandlung der Fabry-Erkrankung dar.
Abstract
Fabry disease is a X-linked recessively inherited metabolic disorder, resulting in a deficient activity of the lysosomal hydrolase α-galactosidase A leading to systemic deposition of glycosphingolipids and multiple organic lesions with a fatal clinical progress in the fourth or fifth decade. We report about a 33-year old male patient with Fabry's disease and typical neurological complications of cerebrovascular events in adolescense and recurrent excruciating pain episodes involving the extremities. Clinical symptoms and diagnostic procedures of this rare metabolic disease will be described. From a therapeutic point of view, the availability of a new enzyme replacement therapy is an important breakthrough for patients with Fabry disease.
Literatur
1 Desnick R J, Ioannou Y A. Alpha-Galactosidase A deficiency: Fabry disease. The metabolic and molecular bases of inherited disease. Vol. New York; McGraw Hill 1995: 2741-2784
2
Menkes D L, O'Neil T J, Saenz K K.
Fabry's disease presenting as syncope, angiokeratomas, and spoke-like cataracts in a young man: discussion of the differential diagnosis.
Mil Med.
1997;
162
773-776
3
Morgan S H, Crawfurd M A.
Anderson-Fabry disease.
Bmj.
1988;
297
872-873
4
Hasholt L. et al .
A Fabry's disease heterozygote with a new mutation: biochemical, ultrastructural, and clinical investigations.
J Med Genet.
1990;
27
303-306
5
Redonnet-Vernhet I. et al .
Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene.
J Med Genet.
1996;
33
682-688
6
Eng C M. et al .
Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease.
N Engl J Med.
2001;
345
9-16
7
Brady R O. et al .
Enzyme replacement therapy in Fabry disease.
J Inherit Metab Dis.
2001;
24, Suppl 2
18-24; discussion 11 - 12
8
Schiffmann R. et al .
Enzyme replacement therapy in Fabry disease: a randomized controlled trial.
Jama.
2001;
285
2743-2749
9
Ziegler R J. et al .
Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
Hum Gene Ther.
1999;
10
1667-1682
10
Platt F M, Butters T D.
New therapeutic prospects for the glycosphingolipid lysosomal storage diseases.
Hum Gene Ther.
1998;
56
421-430
11
Filling-Katz M R. et al .
Carbamazepine in Fabry's disease: effective analgesia with dose- dependent exacerbation of autonomic dysfunction.
Neurology.
1989;
39
598-600
12
Lenoir G. et al .
Fabry's disease. Carbamazepine therapy in acrodyniform syndrome.
Arch Fr Pediatr.
1977;
34
704-716
13
Lockman L A, Hunninghake D B.
Relief of pain of Fabry's disease by diphenylhydantoin.
Neurology.
1973;
23
871-875
14
Gordon K E, Ludman M D, Finley G A.
Successful treatment of painful crises of Fabry disease with low dose morphine.
Pediatr Neurol.
1995;
12
250-251
15
Philippart M.
Treatment of painful crises of Fabry disease with morphine.
Pediatr Neurol.
1995;
13
268
16
Kaye E M. et al .
Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation.
Ann Neurol.
1988;
23
505-509
17
Veber G A de. et al .
Fabry disease: immunocytochemical characterization of neuronal involvement.
Ann Neurol.
1992;
31
409-415
18
Gadoth N, Sandbank U.
Involvement of dorsal root ganglia in Fabry's disease.
J Med Genet.
1983;
20
309-312
19
Hozumi I. et al .
Accumulation of glycosphingolipids in spinal and sympathetic ganglia of a symptomatic heterozygote of Fabry's disease.
J Neurol Sci.
1989;
90
273-280
20
MacDermot J, MacDermot K D.
Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options.
Eur J Pharmacol.
2001;
429
121-125
21
Hilz M J, Stemper B, Kolodny E H.
Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients.
Pain.
2000;
84
361-365
22
Moore D F. et al .
Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.
Stroke.
2002;
33
525-531
23
Moore D F. et al .
Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy.
Circulation.
2001;
104
1506-1512
24
Altarescu G. et al .
Enhanced endothelium-dependent vasodilation in Fabry disease.
Stroke.
2001;
32
1559-1562
25
Itoh Y. et al .
Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease.
J Neurochem.
2001;
79
1217-24
26
Mitsias P, Levine S R.
Cerebrovascular complications of Fabry's disease.
Ann Neurol.
1996;
40
8-17
27
Utsumi K. et al .
High incidence of thrombosis in Fabry's disease.
Intern Med.
1997;
36
327-329
28
Crutchfield K E. et al .
Quantitative analysis of cerebral vasculopathy in patients with Fabry disease.
Neurology.
1998;
50
1746-1749
29
Grewal R P, Barton N W.
Fabry's disease presenting with stroke.
Clin Neurol Neurosurg.
1992;
94
177-179
Dr. med. Volker Busch
Klinik und Poliklinik für Neurologie · Universitätsklinikum Regensburg
Universitätsstraße 84
93053 Regensburg